



Pimozide

Updated: January 16, 2014.

OVERVIEW

Introduction

Pimozide is a conventional antipsychotic used largely in the therapy of Tourette syndrome. Pimozide therapy has not been associated with serum aminotransferase elevations nor with cases of clinically apparent acute liver injury.

Background

Pimozide (pim' oh zide) is a diphenylbutylpiperidine derivative that differs structurally from the phenothiazines and appears to act by blocking dopamine type 2 (D2) receptors. Pimozide has other central and peripheral effects including anticholinergic and alpha adrenergic blockade. Pimozide is indicated for the therapy of severe motor and verbal tics in patients with Tourette syndrome. It has also been used in therapy of schizophrenia. Pimozide was approved for use in the United States in 1984. As therapy of schizophrenia, pimozide has been replaced in large part by the atypical antipsychotics, which have fewer extrapyramidal side effects. Pimozide continues to be used in patients with Tourette syndrome. Pimozide is available as tablets of 1 and 2 mg in generic forms and under the brand name Orap. Typical doses are 1 to 2 mg daily in divided doses, increasing to a maximum of 10 mg daily. Pimozide can prolong the QT interval and, in rare instances, has caused sudden death for which reason the dose should be carefully chosen and drug levels monitored. Common side effects include drowsiness, dizziness, headache, blurred vision, dry mouth, and constipation.

Hepatotoxicity

Liver test abnormalities have not been reported to occur in of patients on pimozide, but the degree and duration of monitoring done in initial studies were not clear. Instances of clinically apparent acute liver injury have not been reported due to pimozide, and thus must be exceedingly rare if they occur.

Mechanism of Injury

Pimozide is extensively metabolized by the liver partially via the cytochrome P450 system (predominantly CYP 2D6) and levels can be seriously elevated in patients who concurrently receive CYP 2D6 inhibitors, particularly in persons who are poor metabolizers of CYP 2D6 substrates. The lack of hepatotoxicity may relate in part to the low dosage used (less than 10 mg daily).

Drug Class: [Antipsychotic Agents](#)

PRODUCT INFORMATION

REPRESENTATIVE TRADE NAMES

Pimozide – Generic, Orap®


DRUG CLASS

Antipsychotic Agents

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

CHEMICAL FORMULA AND STRUCTURE

DRUG	CAS REGISTRY NUMBER	MOLECULAR FORMULA	STRUCTURE
Pimozide	2062-78-4	C ₂₈ H ₂₉ F ₂ N ₃ O	

ANNOTATED BIBLIOGRAPHY

References updated: 16 January 2014

Zimmerman HJ. Neuroleptic drugs. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 483-91.

(Expert review of hepatotoxicity of neuroleptic drugs published in 1999; mentions a single case of cholestatic jaundice due to pimozide).

Larry D, Ripault MP. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 443-62. *(Review of hepatotoxicity of psychiatric agents does not discuss pimozide*

).

Meyer JM. Pharmacotherapy of psychosis and mania. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 417-56.

(Textbook of pharmacology and therapeutics).

Claghorn JL. A double-blind comparison of pimozide vs. trifluoperazine in schizophrenic outpatients. *Curr Ther Res Clin Exp* 1974; 16: 1005-9. PubMed PMID: 4214658.

(Small trial of 6 months of pimozide vs trifluoperazine therapy in 87 subjects with monitoring of serum tests; 3 on pimozide and 6 on trifluoperazine had “some transient laboratory alterations”, but which tests, by how much and when was not defined).

Kolivakis T, Azim H, Kingstone E. A double-blind comparison of pimozide and chlorpromazine in the maintenance care of chronic schizophrenic outpatients. *Curr Ther Res Clin Exp* 1974; 16: 998-1004. PubMed PMID: 4214674.

(Trial of pimozide vs chlorpromazine for 6 months with laboratory monitoring, no mention of ALT elevations or hepatotoxicity).

Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS. Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry. *Drugs* 1976; 12: 1-40. PubMed PMID: 824116.

(Short review of pharmacology, indications and side effects of pimozide; no mention of ALT elevations or hepatotoxicity).

Colvin CL, Tankanow RM. Pimozide: use in Tourette's syndrome. *Drug Intell Clin Pharm* 1985; 19: 421-4. PubMed PMID: 3891283.

(Review of structure, pharmacology and efficacy of pimozide in short term studies in Tourette syndrome; no mention of hepatotoxicity).

Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. *Am J Psychiatry* 1999; 156: 1686-96. PubMed PMID: 10553730.

(Systematic review of 81 articles on weight change with antipsychotics, using change after 10 weeks to compare agents: clozapine +5.7, olanzapine +4.2, chlorpromazine +4.2, risperidone +1.7, loxapine +0.6, haloperidol +0.5, ziprasidone +0.3, molindone -0.1, and pimozide -2.7 kg).

Rogers HL, Bhattaram A, Zineh I, Gobburu J, Mathis M, Laughren TP, Pacanowski M. CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations. *J Clin Psychiatry* 2012; 73: 1187-90. PubMed PMID: 23059146.

(Review of the pharmacogenetics of pimozide and the role of CYP 2D6 and CYP 2D6 inhibitors in its metabolism and adverse events).